Jacobs Levy Equity Management, Inc Mirati Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $383,122 - $524,791	10,604 Added 5.74%	195,320 $7.06 Million
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $5.21 Million - $7.74 Million	142,694 Added 339.57%	184,716 $6.87 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $1.73 Million - $4.14 Million	42,022 New	42,022 $1.9 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $145,252 - $202,551	-914 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $148,113 - $219,606	914 New	914 $201,000

Q3 2018 Nov 14, 2018	SELL	$47.1 - $62.7 $1.11 Million - $1.47 Million	-23,500 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$17.2 - $34.95 $86,000 - $174,750	-5,000 Reduced 17.54%	23,500 $721,000
Q4 2017 Feb 13, 2018	BUY	$12.65 - $19.0 $63,250 - $95,000	5,000 Added 21.28%	28,500 $520,000
Q3 2017 Nov 14, 2017	BUY	$4.7 - $11.7 $57,810 - $143,910	12,300 Added 109.82%	23,500 $275,000
Q2 2017 Nov 09, 2017	BUY	N/A	11,200	11,200 $41,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.